Biogen (BIIB) call put ratio 1 call to 1 put into quarter results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Supermicro raises Q1 FY2027 revenue outlook on AI demand
- Dow outperforms as Wall Street rises, healthcare stocks lead gains
- Crude Inventory Fell 3.06 Million Barrels Last Week - EIA
Biogen (BIIB) Tops Q2 EPS by 43c, Beats on Revenue; Offers FY26 EPS Guidance
July 29, 2026 6:07 AM EDTBiogen (NASDAQ: BIIB) reported Q2 EPS of $3.60, $0.43 better than the analyst estimate of $3.17. Revenue for the quarter came in at $2.74 billion versus the consensus estimate of $2.43 billion.
GUIDANCE:
Biogen sees FY2026 EPS of $12.00-$13.00, versus the consensus of $12.72.
For earnings history and earnings-related data on Biogen (BIIB) click here.
... More


